A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Hoffmann-La Roche
National Cancer Institute (NCI)
INSYS Therapeutics Inc
Duke University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center